LBPH News and Press, Longboard Pharmaceuticals Inc. From 01/02/24

2024-01-02 17:52:42 ET DENVER, Colo., Jan. 2, 2024 ( www.247marketnews.com )- 24/7 Market News covered the following companies today; Longboard Pharmaceuticals Inc (NASDAQ: LBPH), Voyager Therapeutics Inc (NASDAQ: VYGR), Polished.com Inc (AMEX: POL), C4 Therapeutics Inc. (NASDAQ: CCCC),...

2024-01-02 16:55:53 ET Gainers: Bloomin' Brands ( BLMN ) +6% . Arcutis Biotherapeutics ( ARQT ) +6% . Stronghold Digital Mining ( SDIG ) +5% . Longboard Pharmaceuticals ( LBPH ) +4% . Guardant Health ( GH ) +3% . Losers: ...

2024-01-02 16:31:09 ET More on Longboard Pharmaceuticals Longboard stock soars 132% in premarket trading on positive data Seeking Alpha’s Quant Rating on Longboard Pharmaceuticals Historical earnings data for Longboard Pharmaceuticals Financial informa...

2024-01-02 12:56:48 ET More on Mid-day movers & stocks. ENDRA Life Sciences Inc. (NDRA) Q3 2023 Earnings Call Transcript PolyPid Ltd. (PYPD) Q3 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Endra Life Sciences Historical earnings da...

2024-01-02 10:09:39 ET DENVER, Colo., Jan. 2, 2024 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; Longboard Pharmaceuticals Inc (NASDAQ: LBPH), Voyager Therapeutics Inc (NASDAQ: VYGR), Soligenix Inc (NASDAQ: ...

2024-01-02 08:58:56 ET DENVER, Colo., Jan. 2, 2024 ( www.247marketnews.com )- Longboard Pharmaceuticals Inc (NASDAQ: LBPH) reported, this morning, that it’s rapidly moving forward with preparations for its global Phase 3 program, after achieving positive topline data from the PAC...

2024-01-02 08:46:54 ET More on Longboard Pharmaceuticals Seeking Alpha’s Quant Rating on Longboard Pharmaceuticals Historical earnings data for Longboard Pharmaceuticals Financial information for Longboard Pharmaceuticals For further details see: L...

Bexicaserin achieved a median seizure reduction of 53.3% in countable motor seizures compared to 20.8% in the placebo group across the DEE study population A median seizure reduction of 72.1% in Dravet Syndrome (DS), 48.1% in Lennox-Gastaut Syndrome (LGS) and 61.2% in DEE Other was achiev...

• Conference call and webcast to be held tomorrow, January 2, at 8:30am ET (5:30am PT) Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced...

Initiated Single-Ascending Dose (SAD) Phase 1 clinical study evaluating LP659 Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the initiation ...